

# CUMULATIVE CHAPTER TITLES KEYWORD INDEX, VOLUME 1 – 47

acetylcholine receptors, 30, 41; 40, 3  
 acetylcholine transporter, 28, 247  
 acetyl CoA carboxylase (ACC) inhibitors, 45, 95  
 acyl sulfonamide anti-proliferatives, 41, 251  
 adenylate cyclase, 6, 227, 233; 12, 172; 19, 293; 29, 287  
 adenosine, 33, 111  
 adenosine, neuromodulator, 18, 1; 23, 39  
 adenosine receptor ligands, 44, 265  
 A3 adenosine receptors, 38, 121  
 adjuvants, 9, 244  
 ADME by computer, 36, 257  
 ADME, computational models, 42, 449  
 ADME properties, 34, 307  
 adrenal steroidogenesis, 2, 263  
 adrenergic receptor antagonists, 35, 221  
 $\beta$ -adrenergic blockers, 10, 51; 14, 81  
 $\beta$ -adrenergic receptor agonists, 33, 193  
 $\beta_2$ -adrenoceptor agonists, long acting, 41, 237  
 aerosol delivery, 37, 149  
 affinity labeling, 9, 222  
 $\beta_3$ -agonists, 30, 189  
 AIDS, 23, 161, 253; 25, 149  
 AKT kinase inhibitors, 40, 263  
 alcohol consumption, drugs and deterrence, 4, 246  
 aldose reductase, 19, 169  
 alkaloids, 1, 311; 3, 358; 4, 322; 5, 323; 6, 274  
 allergic eosinophilia, 34, 61  
 allergy, 29, 73  
 alopecia, 24, 187  
 allosteric Modulators for GPCR, 47, 441  
 Alzheimer's Disease, 26, 229; 28, 49, 197, 247; 32, 11; 34, 21; 35, 31; 40, 35  
 Alzheimer's Disease Research, 37, 31  
 Alzheimer's Disease Therapies, 37, 197; 40, 35  
 aminocyclitol antibiotics, 12, 110  
 AMPK Activation, 47, 143  
 $\beta$ -amyloid, 34, 21  
 amyloid, 28, 49; 32, 11  
 amyloidogenesis, 26, 229  
 analgesics (analgetic), 1, 40; 2, 33; 3, 36; 4, 37; 5, 31; 6, 34; 7, 31; 8, 20; 9, 11; 10, 12; 11, 23; 12, 20; 13, 41; 14, 31; 15, 32; 16, 41; 17, 21; 18, 51; 19, 1; 20, 21; 21, 21; 23, 11; 25, 11; 30, 11; 33, 11  
 anaplastic lymphoma kinase (ALK) inhibitors, 47, 218  
 androgen action, 21, 179; 29, 225

androgen receptor modulators, 36, 169  
anesthetics, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; 10, 30, 31, 41  
angiogenesis inhibitors, 27, 139; 32, 161  
angiotensin/renin modulators, 26, 63; 27, 59  
animal engineering, 29, 33  
animal healthcare, 36, 319  
animal models, anxiety, 15, 51  
animal models, memory and learning, 12, 30  
Annual Reports in Medicinal Chemistry, 25, 333  
anorexigenic agents, 1, 51; 2, 44; 3, 47; 5, 40; 8, 42; 11, 200; 15, 172  
antagonists, Bcl-2 family proteins, 47, 253  
antagonists, calcium, 16, 257; 17, 71; 18, 79  
antagonists, GABA, 13, 31; 15, 41; 39, 11  
antagonists, narcotic, 7, 31; 8, 20; 9, 11; 10, 12; 11, 23  
antagonists, non-steroidal, 1, 213; 2, 208; 3, 207; 4, 199  
Antagonists, PGD2, 41, 221  
antagonists, steroidal, 1, 213; 2, 208; 3, 207; 4, 199  
antagonists of VLA-4, 37, 65  
anthracycline antibiotics, 14, 288  
antiaging drugs, 9, 214  
antiallergy agents, 1, 92; 2, 83; 3, 84; 7, 89; 9, 85; 10, 80; 11, 51; 12, 70; 13, 51; 14, 51; 15, 59; 17, 51; 18, 61; 19, 93; 20, 71; 21, 73; 22, 73; 23, 69; 24, 61; 25, 61; 26, 113; 27, 109  
antianginals, 1, 78; 2, 69; 3, 71; 5, 63; 7, 69; 8, 63; 9, 67; 12, 39; 17, 71  
anti-angiogenesis, 35, 123  
antianxiety agents, 1, 1; 2, 1; 3, 1; 4, 1; 5, 1; 6, 1; 7, 6; 8, 1; 9, 1; 10, 2; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 19, 11; 20, 1; 21, 11; 22, 11; 23, 19; 24, 11  
antiapoptotic proteins, 40, 245  
antiarrhythmic agents, 41, 169  
antiarrhythmics, 1, 85; 6, 80; 8, 63; 9, 67; 12, 39; 18, 99, 21, 95; 25, 79; 27, 89  
antibacterial resistance mechanisms, 28, 141  
antibacterials, 1, 118; 2, 112; 3, 105; 4, 108; 5, 87; 6, 108; 17, 107; 18, 29, 113; 23, 141; 30, 101; 31, 121; 33, 141; 34, 169; 34, 227; 36, 89; 40, 301  
antibacterial targets, 37, 95  
antibiotic transport, 24, 139  
antibiotics, 1, 109; 2, 102; 3, 93; 4, 88; 5, 75, 156; 6, 99; 7, 99, 217; 8, 104; 9, 95; 10, 109, 246; 11, 89; 11, 271; 12, 101, 110; 13, 103, 149; 14, 103; 15, 106; 17, 107; 18, 109; 21, 131; 23, 121; 24, 101; 25, 119; 37, 149; 42, 349  
antibiotic producing organisms, 27, 129  
antibodies, cancer therapy, 23, 151  
antibodies, drug carriers and toxicity reversal, 15, 233  
antibodies, monoclonal, 16, 243  
antibody drug conjugates, 38, 229; 47, 349  
anticancer agents, mechanical-based, 25, 129  
anticancer drug resistance, 23, 265  
anticoagulants, 34, 81; 36, 79; 37, 85  
anticoagulant agents, 35, 83  
anticoagulant/antithrombotic agents, 40, 85

anticonvulsants, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39, 8, 29; 10, 30; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 19, 11; 20, 11; 21, 11; 23, 19; 24, 11  
 antidepressants, 1, 12; 2, 11; 3, 14; 4, 13; 5, 13; 6, 15; 7, 18; 8, 11; 11, 3; 12, 1; 13, 1; 14, 1; 15, 1; 16, 1; 17, 41; 18, 41; 20, 31; 22, 21; 24, 21; 26, 23; 29, 1; 34, 1  
 antidepressant drugs, new, 41, 23  
 antidiabetics, 1, 164; 2, 176; 3, 156; 4, 164; 6, 192; 27, 219  
 antiepileptics, 33, 61  
 antifungal agents, 32, 151; 33, 173, 35, 157  
 antifungal drug discovery, 38, 163; 41, 299  
 antifungals, 2, 157; 3, 145; 4, 138; 5, 129; 6, 129; 7, 109; 8, 116; 9, 107; 10, 120; 11, 101; 13, 113; 15, 139; 17, 139; 19, 127; 22, 159; 24, 111; 25, 141; 27, 149  
 antiglaucoma agents, 20, 83  
 anti-HCV therapeutics, 34, 129; 39, 175  
 antihyperlipidemics, 15, 162; 18, 161; 24, 147  
 antihypertensives, 1, 59; 2, 48; 3, 53; 4, 47; 5, 49; 6, 52; 7, 59; 8, 52; 9, 57; 11, 61; 12, 60; 13, 71; 14, 61; 15, 79; 16, 73; 17, 61; 18, 69; 19, 61; 21, 63; 22, 63; 23, 59; 24, 51;  
 antiinfective agents, 28, 119  
 antiinflammatory agents, 28, 109; 29, 103  
 anti-inflammatories, 37, 217  
 anti-inflammatories, non-steroidal, 1, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7, 208; 8, 214; 9, 193; 10, 172; 13, 167; 16, 189; 23, 181  
 anti-ischemic agents, 17, 71  
 antimalarial inhibitors, 34, 159  
 antimetabolite cancer chemotherapies, 39, 125  
 antimetabolite concept, drug design, 11, 223  
 antimicrobial drugs—clinical problems and opportunities, 21, 119  
 antimicrobial potentiation, 33, 121  
 antimicrobial peptides, 27, 159  
 antimitotic agents, 34, 139  
 antimycobacterial agents, 31, 161  
 antineoplastics, 2, 166; 3, 150; 4, 154; 5, 144; 7, 129; 8, 128; 9, 139; 10, 131; 11, 110; 12, 120; 13, 120; 14, 132; 15, 130; 16, 137; 17, 163; 18, 129; 19, 137; 20, 163; 22, 137; 24, 121; 28, 167  
 anti-obesity agents, centrally acting, 41, 77  
 antiparasitics, 1, 136, 150; 2, 131, 147; 3, 126, 140; 4, 126; 5, 116; 7, 145; 8, 141; 9, 115; 10, 154; 121; 12, 140; 13, 130; 14, 122; 15, 120; 16, 125; 17, 129; 19, 147; 26, 161  
 antiparkinsonism drugs, 6, 42; 9, 19  
 antiplatelet therapies, 35, 103  
 antipsychotics, 1, 1; 2, 1; 3, 1; 4, 1; 5, 1; 6, 1; 7, 6; 8, 1; 9, 1; 10, 2; 11, 3; 12, 1; 13, 11; 14, 12; 15, 12; 16, 11; 18, 21; 19, 21; 21, 1; 22, 1; 23, 1; 24, 1; 25, 1; 26, 53; 27, 49; 28, 39; 33, 1  
 antiradiation agents, 1, 324; 2, 330; 3, 327; 5, 346  
 anti-resorptive and anabolic bone agents, 39, 53  
 anti-retroviral chemotherapy, 25, 149  
 antiretroviral drug therapy, 32, 131  
 antiretroviral therapies, 35, 177; 36, 129  
 antirheumatic drugs, 18, 171  
 anti-SARS coronavirus chemistry, 41, 183

antisense oligonucleotides, 23, 295; 33, 313  
antisense technology, 29, 297  
antithrombotics, 7, 78; 8, 73; 9, 75; 10, 99; 12, 80; 14, 71; 17, 79; 27, 99; 32, 71  
antithrombotic agents, 29, 103  
antitumor agents, 24, 121  
antitussive therapy, 36, 31  
antiviral agents, 1, 129; 2, 122; 3, 116; 4, 117; 5, 101; 6, 118; 7, 119; 8, 150; 9, 128; 10, 161; 11, 128; 13, 139; 15, 149; 16, 149; 18, 139; 19, 117; 22, 147; 23, 161; 24, 129; 26, 133; 28, 131; 29, 145; 30, 139; 32, 141; 33, 163; 37, 133; 39, 241  
antitussive therapy, 35, 53  
anxiolytics, 26, 1  
apoptosis, 31, 249  
aporphine chemistry, 4, 331  
arachidonate lipoxygenase, 16, 213  
arachidonic acid cascade, 12, 182; 14, 178  
arachidonic acid metabolites, 17, 203; 23, 181; 24, 71  
artemisinin derivatives, 44, 359  
arthritis, 13, 167; 16, 189; 17, 175; 18, 171; 21, 201; 23, 171, 181; 33, 203  
arthritis, immunotherapy, 23, 171  
aryl hydrocarbon receptor activation, 46, 319  
aspartyl proteases, 36, 247  
asthma, 29, 73; 32, 91  
asymmetric synthesis, 13, 282  
Therosclerosis, 1, 178; 2, 187; 3, 172; 4, 178; 5, 180; 6, 150; 7, 169; 8, 183; 15, 162; 18, 161; 21, 189; 24, 147; 25, 169; 28, 217; 32, 101; 34, 101; 36, 57; 40, 71  
atherosclerosis HDL raising therapies, 40, 71  
atherothrombogenesis, 31, 101  
atrial natriuretic factor, 21, 273; 23, 101  
attention deficit hyperactivity disorder, 37, 11; 39, 1  
autoimmune diseases, 34, 257; 37, 217  
autoreceptors, 19, 51  
BACE inhibitors, 40, 35  
bacterial adhesins, 26, 239  
bacterial genomics, 32, 121  
bacterial resistance, 13, 239; 17, 119; 32, 111  
bacterial toxins, 12, 211  
bacterial virulence, 30, 111  
basophil degranulation, biochemistry, 18, 247  
B-cell receptor pathway in inflammatory disease, 45, 175  
Bcl2 family, 31, 249; 33, 253  
behavior, serotonin, 7, 47  
benzodiazepine receptors, 16, 21  
bile acid receptor modulators, 46, 69  
biofilm-associated infections, 39, 155  
bioinformatics, 36, 201  
bioisosteric groups, 38, 333  
bioisosterism, 21, 283

biological factors, 10, 39; 11, 42  
biological membranes, 11, 222  
biological systems, 37, 279  
biopharmaceutics, 1, 331; 2, 340; 3, 337; 4, 302; 5, 313; 6, 264; 7, 259; 8, 332  
biosensor, 30, 275  
biosimulation, 37, 279  
biosynthesis, antibiotics, 12, 130  
biotechnology, drug discovery, 25, 289  
biowarfare pathogens, 39, 165  
blood-brain barrier, 20, 305; 40, 403  
blood enzymes, 1, 233  
bone, metabolic disease, 12, 223; 15, 228; 17, 261; 22, 169  
bone metabolism, 26, 201  
bradykinin-1 receptor antagonists, 38, 111  
bradykinin B2 antagonists, 39, 89  
brain, decade of, 27, 1  
C5a antagonists, 39, 109  
C5a receptor antagonists, 46, 171  
calcium antagonists/modulators, 16, 257; 17, 71; 18, 79; 21, 85  
calcium channels, 30, 51  
calmodulin antagonists, SAR, 18, 203  
cancer, 27, 169; 31, 241; 34, 121; 35, 123; 35, 167  
cancer chemosensitization, 37, 115  
cancer chemotherapy, 29, 165; 37, 125  
cancer cytotoxics, 33, 151  
cancer, drug resistance, 23, 265  
cancer therapy, 2, 166; 3, 150; 4, 154; 5, 144; 7, 129; 8, 128; 9, 139, 151; 10, 131; 11, 110; 12, 120; 13, 120; 14, 132; 15, 130; 16, 137; 17, 163; 18, 129; 21, 257; 23, 151; 37, 225; 39, 125  
cannabinoid receptors, 9, 253; 34, 199  
cannabinoid, receptors, CB1, 40, 103  
cannabinoid (CB2) selective agonists, 44, 227  
capsid assembly pathway modulators, 46, 283  
carbohydrates, 27, 301  
carboxylic acid, metalated, 12, 278  
carcinogenicity, chemicals, 12, 234  
cardiotonic agents, 13, 92; 16, 93; 19, 71  
cardiovascular, 10, 61  
case history: Chantix (varenicline tartrate), 44, 71  
case history: Eliquis™ (Apixaban), 47, 123  
case history: Ixabepilone (ixempra®), 44, 301  
case history -JANUVIA®, 42, 95  
case history -Tegaserod, 42, 195  
case history: Tekturna®/rasilez® (aliskiren), 44, 105  
caspases, 33, 273  
catalysis, intramolecular, 7, 279  
catalytic antibodies, 25, 299; 30, 255  
Cathepsin K, 39, 63

CCR1 antagonists, 39, 117  
CCR2 antagonists, 42, 211  
CCR3 antagonists, 38, 131  
cell adhesion, 29, 215  
cell adhesion molecules, 25, 235  
cell based mechanism screens, 28, 161  
cell cultures, 3D, 47, 367  
cell cycle, 31, 241; 34, 247  
cell cycle kinases, 36, 139  
cell invasion, 14, 229  
cell metabolism, 1, 267  
cell metabolism, cyclic AMP, 2, 286  
cellular pathways, 37, 187  
cellular responses, inflammatory, 12, 152  
CFTR modulators for the treatment of cystic fibrosis, 45, 157  
chemical tools, 40, 339  
chemical proteomic technologies for drug target identification, 45, 345  
cheminformatics, 38, 285  
chemogenomics, 38, 285  
chemoinformatics, 33, 375  
chemokines, 30, 209; 35, 191; 39, 117  
chemotaxis, 15, 224; 17, 139, 253; 24, 233  
chemotherapy of HIV, 38, 173  
cholecystokinin, 18, 31  
cholecystokinin agonists, 26, 191  
cholecystokinin antagonists, 26, 191  
cholesteryl ester transfer protein, 35, 251  
chronic obstructive pulmonary disease, 37, 209  
chronopharmacology, 11, 251  
circadian processes, 27, 11  
circadian rhythm modulation via CK1 inhibition, 46, 33  
*Clostridium difficile* treatments, 43, 269  
CNS medicines, 37, 21  
CNS PET imaging agents, 40, 49  
coagulation, 26, 93; 33, 81  
co-crystals in drug discovery, 43, 373  
cognition enhancers, 25, 21  
cognitive disorders, 19, 31; 21, 31; 23, 29; 31, 11  
collagenase, biochemistry, 25, 177  
collagenases, 19, 231  
colony stimulating factor, 21, 263  
combinatorial chemistry, 34, 267; 34, 287  
combinatorial libraries, 31, 309; 31, 319  
combinatorial mixtures, 32, 261  
complement cascade, 27, 199; 39, 109  
complement inhibitors, 15, 193  
complement system, 7, 228

compound collection enhancement and high throughput screening, 45, 409  
conformation, nucleoside, biological activity, 5, 272  
conformation, peptide, biological activity, 13, 227  
conformational analysis, peptides, 23, 285  
congestive heart failure, 22, 85; 35, 63  
contrast media, NMR imaging, 24, 265  
COPD, 47, 209  
corticotropin-releasing factor, 25, 217; 30, 21; 34, 11; 43, 3  
corticotropin-releasing hormone, 32, 41  
cotransmitters, 20, 51  
CRTh2 antagonists, 46, 119  
CXCR3 antagonists, 40, 215  
cyclic AMP, 2, 286; 6, 215; 8, 224; 11, 291  
cyclic GMP, 11, 291  
cyclic nucleotides, 9, 203; 10, 192; 15, 182  
cyclin-dependent kinases, 32, 171  
cyclooxygenase, 30, 179  
cyclooxygenase-2 inhibitors, 32, 211; 39, 99  
cysteine proteases, 35, 309; 39, 63  
cystic fibrosis, 27, 235; 36, 67  
cytochrome P-450, 9, 290; 19, 201; 32, 295  
cytochrome P-450 inhibition, 44, 535  
cytokines, 27, 209; 31, 269; 34, 219  
cytokine receptors, 26, 221  
database searching, 3D, 28, 275  
DDT-type insecticides, 9, 300  
dengue virus inhibitors, 47, 297  
dermal wound healing, 24, 223  
dermatology and dermatological agents, 12, 162; 18, 181; 22, 201; 24, 177  
designer enzymes, 25, 299  
deuterium in drug discovery and development, 46, 403  
diabetes, 9, 182; 11, 170; 13, 159; 19, 169; 22, 213; 25, 205; 30, 159; 33, 213; 39, 31; 40, 167  
diabetes targets, G-Protein coupled receptors, 42, 129  
Diels-Alder reaction, intramolecular, 9, 270  
dipeptidyl, peptidase 4, inhibitors, 40, 149  
discovery indications, 40, 339  
distance geometry, 26, 281  
diuretic, 1, 67; 2, 59; 3, 62; 6, 88; 8, 83; 10, 71; 11, 71; 13, 61; 15, 100  
DNA binding, sequence-specific, 27, 311; 22, 259  
DNA vaccines, 34, 149  
docking strategies, 28, 275  
dopamine, 13, 11; 14, 12; 15, 12; 16, 11, 103; 18, 21; 20, 41; 22, 107  
dopamine D3, 29, 43  
dopamine D4, 29, 43  
DPP-IV Inhibition, 36, 191  
drug attrition associated with physicochemical properties, 45, 393  
drug abuse, 43, 61

drug abuse, CNS agents, 9, 38  
drug allergy, 3, 240  
drug carriers, antibodies, 15, 233  
drug carriers, liposomes, 14, 250  
drug delivery systems, 15, 302; 18, 275; 20, 305  
drug design, 34, 339  
drug design, computational, 33, 397  
drug design, knowledge and intelligence in, 41, 425  
drug design, metabolic aspects, 23, 315  
drug discovery, 17, 301; 34, 307  
drug discovery, bioactivation in, 41, 369  
drug discovery for neglected tropical diseases, 45, 277  
drug disposition, 15, 277  
drug metabolism, 3, 227; 4, 259; 5, 246; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201; 13, 196, 304; 14; 188, 16, 319; 17, 333; 23, 265, 315; 29, 307  
drug receptors, 25, 281  
drug repositioning, 46, 385  
drug resistance, 23, 265  
drug safety, 40, 387  
dynamic modeling, 37, 279  
dyslipidemia and insulin resistance enzyme targets, 42, 161  
EDRF, 27, 69  
elderly, drug action, 20, 295  
electrospray mass spectrometry, 32, 269  
electrosynthesis, 12, 309  
enantioselectivity, drug metabolism, 13, 304  
endorphins, 13, 41; 14, 31; 15, 32; 16, 41; 17, 21; 18, 51  
endothelin, 31, 81; 32, 61  
endothelin antagonism, 35, 73  
endothelin antagonists, 29, 65, 30, 91  
enzymatic monooxygenation reactions, 15, 207  
enzyme induction, 38, 315  
enzyme inhibitors, 7, 249; 9, 234; 13, 249  
enzyme immunoassay, 18, 285  
enzymes, anticancer drug resistance, 23, 265  
enzymes, blood, 1, 233  
enzymes, proteolytic inhibition, 13, 261  
enzyme structure–function, 22, 293  
enzymic synthesis, 19, 263; 23, 305  
epitopes for antibodies, 27, 189  
erectile dysfunction, 34, 71  
Eribulin (HALAVEN<sup>TM</sup>) case history, 46, 227  
estrogen receptor, 31, 181  
estrogen receptor modulators, SERMS, 42, 147  
ethnobotany, 29, 325  
excitatory amino acids, 22, 31; 24, 41; 26, 11; 29, 53  
ex-vivo approaches, 35, 299



factor VIIa, 37, 85  
factor Xa, 31, 51; 34, 81  
factor Xa inhibitors, 35, 83  
Fc receptor structure, 37, 217  
fertility control, 10, 240; 14, 168; 21, 169  
filarial nematodes, 35, 281  
fluorine in the discovery of CNS agents, 45, 429  
FMS kinase inhibitors, 44, 211  
formulation in drug discovery, 43, 419  
forskolin, 19, 293  
fragment-based lead discovery, 42, 431  
free radical pathology, 10, 257; 22, 253  
fungal nail infections, 40, 323  
fungal resistance, 35, 157  
G-proteins, 23, 235  
G-proteins coupled receptor modulators, 37, 1  
GABA, antagonists, 13, 31; 15, 41  
galanin receptors, 33, 41  
gamete biology, fertility control, 10, 240  
gastrointestinal agents, 1, 99; 2, 91; 4, 56; 6, 68; 8, 93; 10, 90; 12, 91; 16, 83; 17, 89; 18, 89; 20, 117; 23, 201, 38, 89  
gastrointestinal prokinetic agents, 41, 211, 46, 135  
gastrointestinal tracts of mammals, 43, 353  
gender based medicine, 33, 355  
gene expression, 32, 231  
gene expression, inhibitors, 23, 295  
gene knockouts in mice as source of new targets, 44, 475  
gene targeting technology, 29, 265  
gene therapy, 8, 245; 30, 219  
genetically modified crops, 35, 357  
gene transcription, regulation of, 27, 311  
genomic data mining, 41, 319  
genomics, 34, 227; 40, 349  
ghrelin receptor modulators, 38, 81  
glucagon, 34, 189  
glucagon, mechanism, 18, 193  
glucagon receptor antagonists, 43, 119  
 $\beta$ -D-glucans, 30, 129  
glucocorticoid receptor modulators, 37, 167  
glucocorticosteroids, 13, 179  
Glucokinase Activators, 41, 141  
glutamate, 31, 31  
glycine transporter-1 inhibitors, 45, 19  
glycoconjugate vaccines, 28, 257  
glycogen synthase kinase-3 (GSK-3), 40, 135; 44, 3  
glycolysis networks model, 43, 329  
glycopeptide antibiotics, 31, 131

glycoprotein IIb/IIIa antagonists, 28, 79  
glycosylation, non-enzymatic, 14, 261  
gonadal steroid receptors, 31, 11  
gonadotropin receptor ligands, 44, 171  
gonadotropin releasing hormone, 30, 169; 39, 79  
GPIIb/IIIa, 31, 91  
Gpr119 agonists, 44, 149  
GPR40 (FFAR1) modulators, 43, 75  
G-Protein coupled receptor inverse agonists, 40, 373  
G protein-coupled receptors, 35, 271  
gram-negative pathogen antibiotics, 46, 245  
growth factor receptor kinases, 36, 109  
growth factors, 21, 159; 24, 223; 28, 89  
growth hormone, 20, 185  
growth hormone secretagogues, 28, 177; 32, 221  
guanylyl cyclase, 27, 245  
hallucinogens, 1, 12; 2, 11; 3, 14; 4, 13; 5, 23; 6, 24  
HDL cholesterol, 35, 251  
HDL modulating therapies, 42, 177  
health and climate change, 38, 375  
heart disease, ischemic, 15, 89; 17, 71  
heart failure, 13, 92; 16, 93; 22, 85  
hedgehog pathway inhibitors, 44, 323  
HCV antiviral agents, 39, 175  
HDAC inhibitors and LSD1 inhibitors, 45, 245  
helicobacter pylori, 30, 151  
hemoglobins, 34, 159  
hemorheologic agents, 17, 99  
hepatitis C viral inhibitors, 44, 397  
hepatitis C virus inhibitors of non-enzymatic viral proteins, 46, 263  
herbicides, 17, 311  
heterocyclic chemistry, 14, 278  
HIF prolyl hydroxylase, 45, 123  
high throughput screening, 33, 293  
histamine H3 receptor agents, 33, 31; 39, 45  
histamine H3 receptor antagonists, 42, 49  
histone deacetylase inhibitors, 39, 145  
hit-to-lead process, 39, 231  
HIV co-receptors, 33, 263  
HIV-1 integrase strand transfer inhibitors, 45, 263  
HIV prevention strategies, 40, 277  
HIV protease inhibitors, 26, 141; 29, 123  
HIV reverse transcriptase inhibitors, 29, 123  
HIV therapeutics, 40, 291  
HIV vaccine, 27, 255  
HIV viral entry inhibitors, CCR5 and CXCR4, 42, 301  
homeobox genes, 27, 227

hormones, glycoprotein, 12, 211  
hormones, non-steroidal, 1, 191; 3, 184  
hormones, peptide, 5, 210; 7, 194; 8, 204; 10, 202; 11, 158; 16, 199  
hormones, steroid, 1, 213; 2, 208; 3, 207; 4, 199  
host modulation, infection, 8, 160; 14, 146; 18, 149  
Hsp90 inhibitors, 40, 263  
5-HT2C receptor modulator, 37, 21  
human dose projections, 43, 311  
human gene therapy, 26, 315; 28, 267  
human retrovirus regulatory proteins, 26, 171  
hybrid antibacterial agents, 43, 281  
11  $\beta$ -hydroxysteroid dehydrogenase type 1 inhibitors, 41, 127  
5-hydroxytryptamine, 2, 273; 7, 47; 21, 41  
5-hydroxytryptamine -5-HT5A, 5-HT6, and 5-HT7, 43, 25  
hypercholesterolemia, 24, 147  
hypersensitivity, delayed, 8, 284  
hypersensitivity, immediate, 7, 238; 8, 273  
hypertension, 28, 69  
hypertension, etiology, 9, 50  
hypnotics, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; 10, 30; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22, 16; 31; 17, 11; 18, 11; 19, 11; 22, 11  
ICE gene family, 31, 249  
IgE, 18, 247  
I $\kappa$ B kinase inhibitors, 43, 155  
Immune cell signaling, 38, 275  
immune mediated idiosyncratic drug hypersensitivity, 26, 181  
immune system, 35, 281  
immunity, cellular mediated, 17, 191; 18, 265  
immunoassay, enzyme, 18, 285  
immunomodulatory proteins, 35, 281  
immunophilins, 28, 207  
immunostimulants, arthritis, 11, 138; 14, 146  
immunosuppressants, 26, 211; 29, 175  
immunosuppressive drug action, 28, 207  
immunosuppressives, arthritis, 11, 138  
immunotherapy, cancer, 9, 151; 23, 151  
immunotherapy, infectious diseases, 18, 149; 22, 127  
immunotherapy, inflammation, 23, 171  
infections, sexually transmitted, 14, 114  
infectious disease strategies, 41, 279  
inflammation, 22, 245; 31, 279  
inflammation, immunomodulatory approaches, 23, 171  
inflammation, proteinases in, 28, 187  
inflammatory bowel disease, 24, 167, 38, 141  
inflammatory targets for the treatment of atherosclerosis, 47, 223  
inhibition of bacterial fatty acid biosynthesis, 45, 295  
inhibitors, AKT/PKB kinase, 42, 365

inhibitors and modulators, amyloid secretase, 42, 27  
inhibitors, anti-apoptotic proteins, 40, 245  
inhibitors, cathepsin K, 42, 111  
inhibitors, complement, 15, 193  
inhibitors, connective tissue, 17, 175  
inhibitors, dipeptidyl peptidase 4, 40, 149  
inhibitors, enzyme, 13, 249  
inhibitors, glutathione S-transferase, 42, 321  
inhibitors, HCV, 42, 281  
inhibitors, histone deacetylase, 42, 337  
inhibitors, influenza neuraminidase, 41, 287  
inhibitors, irreversible, 9, 234; 16, 289  
inhibitors. MAP kinases, 42, 265  
inhibitors, mitotic kinesin, 41, 263  
inhibitors, monoamine reuptake, 42, 13  
inhibitors, mycobacterial type II topoisomerase, 47, 319  
inhibitors, PDEs, 42, 3  
inhibitors, platelet aggregation, 6, 60  
inhibitors, proteolytic enzyme, 13, 261  
inhibitors, renin, 41, 155  
inhibitors, renin-angiotensin, 13, 82  
inhibitors, reverse transcription, 8, 251  
inhibitors, spleen tyrosine kinase (Syk), 42, 379  
inhibitors, transition state analogs, 7, 249  
inorganic chemistry, medicinal, 8, 294  
inosine monophosphate dehydrogenase, 35, 201  
inositol triphosphate receptors, 27, 261  
insecticides, 9, 300; 17, 311  
insomnia treatments, 42, 63  
in silico approaches, prediction of human volume of distribution, 42, 469  
insulin, mechanism, 18, 193  
insulin sensitizers, 47, 177  
insulin-like growth factor receptor (IGF-1R) inhibitors, 44, 281  
integrins, 31, 191  
 $\beta_2$ —integrin Antagonist, 36, 181  
integrin alpha 4 beta 1 (VLA-4), 34, 179  
intellectual property, 36, 331  
interferon, 8, 150; 12, 211; 16, 229; 17, 151  
interleukin-1, 20, 172; 22, 235; 25, 185; 29, 205, 33, 183  
interleukin-2, 19, 191  
interoceptive discriminative stimuli, animal model of anxiety, 15, 51  
intracellular signaling targets, 37, 115  
intramolecular catalysis, 7, 279  
ion channel modulators, 37, 237  
ion channels, ligand gated, 25, 225  
ion channels, voltage-gated, 25, 225  
ionophores, monocarboxylic acid, 10, 246

ionotropic GABA receptors, 39, 11  
iron chelation therapy, 13, 219  
irreversible ligands, 25, 271  
ischemia/reperfusion, CNS, 27, 31  
ischemic injury, CNS, 25, 31  
isotopes, stable, 12, 319; 19, 173  
isotopically labeled compounds in drug discovery, 44, 515  
JAK3 Inhibitors, 44, 247  
JAKs, 31, 269  
Janus kinase 2 (JAK2) inhibitors, 45, 211  
ketolide antibacterials, 35, 145  
Kv7 Modulators, 46, 53  
 $\beta$ -lactam antibiotics, 11, 271; 12, 101; 13, 149; 20, 127, 137; 23, 121; 24, 101  
 $\beta$ -lactamases, 13, 239; 17, 119; 43, 247  
LDL cholesterol, 35, 251  
learning, 3, 279; 16, 51  
leptin, 32, 21  
leukocyte elastase inhibitors, 29, 195  
leukocyte motility, 17, 181  
leukotriene biosynthesis inhibitors, 40, 199  
leukotriene modulators, 32, 91  
leukotrienes, 17, 291; 19, 241; 24, 71  
LHRH, 20, 203; 23, 211  
lipid metabolism, 9, 172; 10, 182; 11, 180; 12, 191; 13, 184; 14, 198; 15, 162  
lipoproteins, 25, 169  
liposomes, 14, 250  
lipoxygenase, 16, 213; 17, 203  
LXR agonists, 43, 103  
lymphocytes, delayed hypersensitivity, 8, 284  
macrocyclic immunomodulators, 25, 195  
macrolide antibacterials, 35, 145  
macrolide antibiotics, 25, 119  
macrophage migration inhibitor factor, 33, 243  
magnetic resonance, drug binding, 11, 311  
malaria, 31, 141; 34, 349, 38, 203  
male contraception, 32, 191  
managed care, 30, 339  
MAP kinase, 31, 289  
market introductions, 19, 313; 20, 315; 21, 323; 22, 315; 23, 325; 24, 295; 25, 309; 26, 297; 27, 321; 28, 325; 29, 331; 30, 295; 31, 337; 32, 305; 33, 327  
mass spectrometry, 31, 319; 34, 307  
mass spectrometry, of peptides, 24, 253  
mass spectrometry, tandem, 21, 213; 21, 313  
mast cell degranulation, biochemistry, 18, 247  
matrix metalloproteinase, 37, 209  
matrix metalloproteinase inhibitors, 35, 167  
mechanism based, anticancer agents, 25, 129

mechanism, drug allergy, 3, 240  
mechanism of action in drug discovery, 46, 301  
mechanisms of antibiotic resistance, 7, 217; 13, 239; 17, 119  
medicinal chemistry, 28, 343; 30, 329; 33, 385; 34, 267  
melanin-concentrating hormone, 40, 119  
melanocortin-4 receptor, 38, 31  
melatonin, 32, 31  
melatonin agonists, 39, 21  
membrane function, 10, 317  
membrane regulators, 11, 210  
membranes, active transport, 11, 222  
memory, 3, 279; 12, 30; 16, 51  
metabolism, cell, 1, 267; 2, 286  
metabolism, drug, 3, 227; 4, 259; 5, 246; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201; 13, 196, 304; 14, 188; 23, 265, 315  
metabolism, lipid, 9, 172; 10, 182; 11, 180; 12, 191; 14, 198  
metabolism, mineral, 12, 223  
metabonomics, 40, 387  
metabotropic glutamate receptor, 35, 1, 38, 21  
metabotropic glutamate receptor (group III) modulators, 46, 3  
metal carbonyls, 8, 322  
metalloproteinases, 31, 231; 33, 131  
metals, disease, 14, 321  
metastasis, 28, 151  
methyl lysine, 45, 329  
mGluR2 activators and mGluR5 blockers, 47, 71  
microbial genomics, 37, 95  
microbial products screening, 21, 149  
microRNAs as therapeutics, 46, 351  
microtubule stabilizing agents, 37, 125  
microwave-assisted chemistry, 37, 247  
migraine, 22, 41; 32, 1  
mineralocorticoid receptor antagonists, 46, 89  
mitogenic factors, 21, 237  
mitotic kinesin inhibitors, 39, 135  
modified serum lipoproteins, 25, 169  
modulators of transient receptor potential ion channels, 45, 37  
molecular diversity, 26, 259, 271; 28, 315; 34, 287  
molecular libraries screening center network, 42, 401  
molecular modeling, 22, 269; 23, 285  
monoclonal antibodies, 16, 243; 27, 179; 29, 317  
monoclonal antibody cancer therapies, 28, 237  
monooxygenases, cytochrome P-450, 9, 290  
mTOR inhibitors, 43, 189  
multi-factorial diseases, basis of, 41, 337  
multivalent ligand design, 35, 321  
muscarinic agonists/antagonists, 23, 81; 24, 31; 29, 23

muscle relaxants, 1, 30; 2, 24; 3, 28; 4, 28; 8, 37  
muscular disorders, 12, 260  
mutagenicity, mutagens, 12, 234  
mutagenesis, SAR of proteins, 18, 237  
myocardial ischemia, acute, 25, 71  
nanotechnology therapeutics, 47, 239  
narcotic antagonists, 7, 31; 8, 20; 9, 11; 10, 12; 11, 23; 13, 41  
natriuretic agents, 19, 253  
natural products, 6, 274; 15, 255; 17, 301; 26, 259; 32, 285  
natural killer cells, 18, 265  
neoplasia, 8, 160; 10, 142  
neuritic plaque in Alzheimer's disease, 45, 315  
neurodegeneration, 30, 31  
neurodegenerative disease, 28, 11  
neuroinflammation, 47, 37  
neurokinin antagonists, 26, 43; 31, 111; 32, 51; 33, 71; 34, 51  
neurological disorders, 31, 11  
neuronal calcium channels, 26, 33  
neuronal cell death, 29, 13  
neuropathic pain, 38, 1  
neuropeptides, 21, 51; 22, 51  
neuropeptide Y, 31, 1; 32, 21; 34, 31  
neuropeptide Y receptor modulators, 38, 61  
neuropeptide receptor antagonists, 38, 11  
neuropharmacokinetic parameters in CNS drug discovery, 45, 55  
neuroprotection, 29, 13  
neuroprotective agents, 41, 39  
neurotensin, 17, 31  
neurotransmitters, 3, 264; 4, 270; 12, 249; 14, 42; 19, 303  
neutrophilic factors, 25, 245; 28, 11  
neutrophil chemotaxis, 24, 233  
niacin receptor GPR109A agonists, 45, 73  
nicotinic acetylcholine receptor, 22, 281; 35, 41  
nicotinic acetylcholine receptor modulators, 40, 3  
NIH in preclinical drug development, 45, 361  
nitric oxide synthase, 29, 83; 31, 221; 44, 27  
NMDA antagonists, 47, 89  
NMR, 27, 271  
NMR in biological systems, 20, 267  
NMR imaging, 20, 277; 24, 265  
NMR methods, 31, 299  
NMR, protein structure determination, 23, 275  
non-ATP competitive protein kinase inhibitors, 47, 459  
non-enzymatic glycosylation, 14, 261  
non-HIV antiviral agents, 36, 119, 38, 213  
non-nutritive, sweeteners, 17, 323  
non-peptide agonists, 32, 277

non-peptidic d-opioid agonists, 37, 159  
non-steroidal antiinflammatories, 1, 224; 2, 217; 3, 215; 4, 207; 5, 225; 6, 182; 7, 208; 8, 214; 9, 193; 10, 172; 13, 167; 16, 189  
non-steroidal glucocorticoid receptor agonists, 43, 141  
nonstructural protein 5A (NS5A) replication complex inhibitors, 47, 331  
notch pathway modulators, 47, 267  
novel analgesics, 35, 21  
NSAIDs, 37, 197  
nuclear hormone receptor/steroid receptor coactivator inhibitors, 44, 443  
nuclear orphan receptors, 32, 251  
nucleic acid–drug interactions, 13, 316  
nucleic acid, sequencing, 16, 299  
nucleic acid, synthesis, 16, 299  
nucleoside conformation, 5, 272  
nucleosides, 1, 299; 2, 304; 3, 297; 5, 333; 39, 241  
nucleotide metabolism, 21, 247  
nucleotides, 1, 299; 2, 304; 3, 297; 5, 333; 39, 241  
nucleotides, cyclic, 9, 203; 10, 192; 15, 182  
obesity, 1, 51; 2, 44; 3, 47; 5, 40; 8, 42; 11, 200; 15, 172; 19, 157; 23, 191; 31, 201; 32, 21  
obesity therapeutics, 38, 239  
obesity treatment, 37, 1  
oligomerisation, 35, 271  
oligonucleotides, inhibitors, 23, 295  
oncogenes, 18, 225; 21, 159, 237  
opioid receptor, 11, 33; 12, 20; 13, 41; 14, 31; 15, 32; 16, 41; 17, 21; 18, 51; 20, 21; 21, 21  
opioid receptor antagonists, 45, 143  
opioids, 12, 20; 16, 41; 17, 21; 18, 51; 20, 21; 21, 21  
opportunistic infections, 29, 155  
oral pharmacokinetics, 35, 299  
organocopper reagents, 10, 327  
osteoarthritis, 22, 179  
osteoporosis, 22, 169; 26, 201; 29, 275; 31, 211  
oxazolidinone antibacterials, 35, 135  
oxytocin antagonists and agonists, 41, 409  
P38a MAP kinase, 37, 177  
P-glycoprotein, multidrug transporter, 25, 253  
pain therapeutics, 46, 19  
parallel synthesis, 34, 267  
parasite biochemistry, 16, 269  
parasitic infection, 36, 99  
patents in drug discovery, 45, 449  
patents in medicinal chemistry, 22, 331  
pathophysiology, plasma membrane, 10, 213  
PDE IV inhibitors, 31, 71  
PDE7 inhibitors, 40, 227



penicillin binding proteins, 18, 119  
peptic ulcer, 1, 99; 2, 91; 4, 56; 6, 68; 8, 93; 10, 90; 12, 91; 16, 83; 17, 89; 18, 89; 19, 81; 20, 93; 22, 191; 25, 159  
peptide-1, 34, 189  
peptide conformation, 13, 227; 23, 285  
peptide hormones, 5, 210; 7, 194; 8, 204; 10, 202; 11, 158, 19, 303  
peptide hypothalamus, 7, 194; 8, 204; 10, 202; 16, 199  
peptide libraries, 26, 271  
peptide receptors, 25, 281; 32, 277  
peptide, SAR, 5, 266  
peptide stability, 28, 285  
peptide synthesis, 5, 307; 7, 289; 16, 309  
peptide synthetic, 1, 289; 2, 296  
peptide thyrotropin, 17, 31  
peptidomimetics, 24, 243  
periodontal disease, 10, 228  
peptidyl prolyl isomerase inhibitors, 46, 337  
peroxisome proliferator — activated receptors, 38, 71  
PET, 24, 277  
PET and SPECT tracers for brain imaging, 47, 105  
PET imaging agents, 40, 49  
PET ligands, 36, 267  
pharmaceutics, 1, 331; 2, 340; 3, 337; 4, 302; 5, 313; 6, 254, 264; 7, 259; 8, 332  
pharmaceutical innovation, 40, 431  
pharmaceutical productivity, 38, 383  
pharmaceutical proteins, 34, 237  
pharmacogenetics, 35, 261; 40, 417  
pharmacogenomics, 34, 339  
pharmacokinetics, 3, 227, 337; 4, 259, 302; 5, 246, 313; 6, 205; 8, 234; 9, 290; 11, 190; 12, 201; 13, 196, 304; 14, 188, 309; 16, 319; 17, 333  
pharmacophore identification, 15, 267  
pharmacophoric pattern searching, 14, 299  
phosphatidyl-inositol-3-kinases (PI3Ks) inhibitors, 44, 339  
phosphodiesterase, 31, 61  
phosphodiesterase 4 inhibitors, 29, 185; 33, 91; 36, 41  
phosphodiesterase 5 inhibitors, 37, 53  
phospholipases, 19, 213; 22, 223; 24, 157  
phospholipidosis, 46, 419  
physicochemical parameters, drug design, 3, 348; 4, 314; 5, 285  
physicochemical properties and ligand efficiency and drug safety risks, 45, 381  
pituitary hormones, 7, 194; 8, 204; 10, 202  
plants, 34, 237  
plasma membrane pathophysiology, 10, 213  
plasma protein binding, 31, 327  
plasma protein binding, free drug principle, 42, 489  
plasminogen activator, 18, 257; 20, 107; 23, 111; 34, 121  
plasmon resonance, 33, 301

platelet activating factor (PAF), 17, 243; 20, 193; 24, 81  
platelet aggregation, 6, 60  
pluripotent stem cells as human disease models, 46, 369  
poly(ADP-ribose)polymerase (PARP) inhibitors, 45, 229  
polyether antibiotics, 10, 246  
polyamine metabolism, 17, 253  
polyamine spider toxins, 24, 287  
polymeric reagents, 11, 281  
positron emission tomography, 24, 277; 25, 261; 44, 501  
potassium channel activators, 26, 73  
potassium channel antagonists, 27, 89  
potassium channel blockers, 32, 181  
potassium channel openers, 24, 91, 30, 81  
potassium channel modulators, 36, 11  
potassium channels, 37, 237  
pregnane X receptor and CYP3A4 enzyme, 43, 405  
privileged structures, 35, 289  
prodrugs, 10, 306; 22, 303  
prodrug discovery, oral, 41, 395  
profiling of compound libraries, 36, 277  
programmed cell death, 30, 239  
prolactin secretion, 15, 202  
prostacyclin, 14, 178  
prostaglandins, 3, 290; 5, 170; 6, 137; 7, 157; 8, 172; 9, 162; 11, 80; 43, 293  
prostanoid receptors, 33, 223  
prostatic disease, 24, 197  
protease inhibitors for COPD, 43, 171  
proteases, 28, 151  
proteasome, 31, 279  
protein C, 29, 103  
protein growth factors, 17, 219  
proteinases, arthritis, 14, 219  
protein kinases, 18, 213; 29, 255  
protein kinase C, 20, 227; 23, 243  
protein phosphatases, 29, 255  
protein-protein interactions, 38, 295; 44, 51  
protein structure determination, NMR, 23, 275  
protein structure modeling, 39, 203  
protein structure prediction, 36, 211  
protein structure project, 31, 357  
protein tyrosine kinases, 27, 169  
protein tyrosine phosphatase, 35, 231  
proteomics, 36, 227  
psoriasis, 12, 162; 32, 201  
psychiatric disorders, 11, 42  
psychoses, biological factors, 10, 39  
psychotomimetic agents, 9, 27

pulmonary agents, 1, 92; 2, 83; 3, 84; 4, 67; 5, 55; 7, 89; 9, 85; 10, 80; 11, 51; 12, 70; 13, 51; 14, 51; 15, 59; 17, 51; 18, 61; 20, 71; 21, 73; 22, 73; 23, 69; 24, 61; 25, 61; 26, 113; 27, 109  
pulmonary disease, 34, 111  
pulmonary hypertension, 37, 41  
pulmonary inflammation, 31, 71  
pulmonary inhalation technology, 41, 383  
purine and pyrimide nucleotide (P2) receptors, 37, 75  
purine-binding enzymes, 38, 193  
purinoceptors, 31, 21  
QT interval prolongation, 39, 255  
quantitative SAR, 6, 245; 8, 313; 11, 301; 13, 292; 17, 281  
quinolone antibacterials, 21, 139; 22, 117; 23, 133  
radioimmunoassays, 10, 284  
radioisotope labeled drugs, 7, 296  
radioimaging agents, 18, 293  
radioligand binding, 19, 283  
radiosensitizers, 26, 151  
ras farnesyltransferase, 31, 171  
ras GTPase, 26, 249  
ras oncogene, 29, 165  
receptor binding, 12, 249  
receptor mapping, 14, 299; 15, 267; 23, 285  
receptor modeling, 26, 281  
receptor modulators, nuclear hormone, 41, 99  
receptor, concept and function, 21, 211  
receptors, acetylcholine, 30, 41  
receptors, adaptive changes, 19, 241  
receptors, adenosine, 28, 295; 33, 111  
receptors, adrenergic, 15, 217  
receptors, b-adrenergic blockers, 14, 81  
receptors, benzodiazepine, 16, 21  
receptors, cell surface, 12, 211  
receptors, drug, 1, 236; 2, 227; 8, 262  
receptors, G-protein coupled, 23, 221, 27, 291  
receptors, G-protein coupled CNS, 28, 29  
receptors, histamine, 14, 91  
receptors, muscarinic, 24, 31  
receptors, neuropeptide, 28, 59  
receptors, neuronal BZD, 28, 19  
receptors, neurotransmitters, 3, 264; 12, 249  
receptors, neuroleptic, 12, 249  
receptors, opioid, 11, 33; 12, 20; 13, 41; 14, 31; 15, 32; 16, 41; 17, 21  
receptors, peptide, 25, 281  
receptors, serotonin, 23, 49  
receptors, sigma, 28, 1  
recombinant DNA, 17, 229; 18, 307; 19, 223  
recombinant therapeutic proteins, 24, 213

renal blood flow, 16, 103  
renin, 13, 82; 20, 257  
reperfusion injury, 22, 253  
reproduction, 1, 205; 2, 199; 3, 200; 4, 189  
resistant organisms, 34, 169  
respiratory syncytial virus, 43, 229  
respiratory tract infections, 38, 183  
retinoids, 30, 119  
reverse transcription, 8, 251  
RGD-containing proteins, 28, 227  
rheumatoid arthritis, 11, 138; 14, 219; 18, 171; 21, 201; 23, 171, 181  
rho-kinase inhibitors, 43, 87  
ribozymes, 30, 285  
RNAi, 38, 261  
safety testing of drug metabolites, 44, 459  
SAR, quantitative, 6, 245; 8, 313; 11, 301; 13, 292; 17, 291  
same brain, new decade, 36, 1  
schizophrenia, treatment of, 41, 3  
secretase inhibitors, 35, 31; 38, 41  
secretase inhibitors and modulators, 47, 55  
sedative-hypnotics, 7, 39; 8, 29; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 19, 11; 22, 11  
sedatives, 1, 30; 2, 24; 3, 28; 4, 28; 7, 39; 8, 29; 10, 30; 11, 13; 12, 10; 13, 21; 14, 22; 15, 22; 16, 31; 17, 11; 18, 11; 20, 1; 21, 11  
semicarbazide sensitive amine oxidase and VAP-1, 42, 229  
sequence-defined oligonucleotides, 26, 287  
serine protease inhibitors in coagulation, 44, 189  
serine proteases, 32, 71  
SERMs, 36, 149  
serotonergics, central, 25, 41; 27, 21  
serotonergics, selective, 40, 17  
serotonin, 2, 273; 7, 47; 26, 103; 30, 1; 33, 21  
serotonin receptor, 35, 11  
serum lipoproteins, regulation, 13, 184  
sexually-transmitted infections, 14, 114  
SGLT2 inhibitors, 46, 103  
SH2 domains, 30, 227  
SH3 domains, 30, 227  
silicon, in biology and medicine, 10, 265  
sickle cell anemia, 20, 247  
signal transduction pathways, 33, 233  
skeletal muscle relaxants, 8, 37  
sleep, 27, 11; 34, 41  
slow-reacting substances, 15, 69; 16, 213; 17, 203, 291  
Smac mimetics as apoptosis inhibitors, 46, 211  
SNPs, 38, 249  
sodium/calcium exchange, 20, 215

sodium channel blockers, 41, 59; 43, 43  
sodium channels, 33, 51  
solid-phase synthesis, 31, 309  
solid state organic chemistry, 20, 287  
solute active transport, 11, 222  
somatostatin, 14, 209; 18, 199; 34, 209  
sphingomyelin signaling path, 43, 203  
sphingosine-1-phosphate-1 receptor agonists, 47, 195  
sphingosine 1 receptor modulators, 42, 245  
spider toxins, 24, 287  
SRS, 15, 69; 16, 213; 17, 203, 291  
Statins, 37, 197; 39, 187  
Statins, pleiotropic effects of, 39, 187  
STATs, 31, 269  
stereochemistry, 25, 323  
steroid hormones, 1, 213; 2, 208; 3, 207; 4, 199  
stroidogenesis, adrenal, 2, 263  
steroids, 2, 312; 3, 307; 4, 281; 5, 192, 296; 6, 162; 7, 182; 8, 194; 11, 192  
stimulants, 1, 12; 2, 11; 3, 14; 4, 13; 5, 13; 6, 15; 7, 18; 8, 11  
stroke, pharmacological approaches, 21, 108  
stromelysin, biochemistry, 25, 177  
structural genomics, 40, 349  
structure-based drug design, 27, 271; 30, 265; 34, 297  
substance P, 17, 271; 18, 31  
substituent constants, 2, 347  
suicide enzyme inhibitors, 16, 289  
superoxide dismutases, 10, 257  
superoxide radical, 10, 257  
sweeteners, non-nutritive, 17, 323  
synthesis, asymmetric, 13, 282  
synthesis, computer-assisted, 12, 288; 16, 281; 21, 203  
synthesis, enzymic, 23, 305  
systems biology and kinase signaling, 42, 393  
T-cells, 27, 189; 30, 199; 34, 219  
tachykinins, 28, 99  
targeted covalent enzyme inhibitors, 47, 413  
target identification, 41, 331  
taxol, 28, 305  
technology, providers and integrators, 33, 365  
tetracyclines, 37, 105  
Th17 and Treg signaling pathways, 46, 155  
thalidomide, 30, 319  
therapeutic antibodies, s,36, 237  
thrombin, 30, 71, 31, 51; 34, 81  
thrombolytic agents, 29, 93  
thrombosis, 5, 237; 26, 93; 33, 81  
thromboxane receptor antagonists, 25, 99

thromboxane synthase inhibitors, 25, 99  
thromboxane synthetase, 22, 95  
thromboxanes, 14, 178  
thyrotropin releasing hormone, 17, 31  
tissue factor pathway, 37, 85  
TNF- $\alpha$ , 32, 241  
TNF- $\alpha$  converting enzyme, 38, 153  
toll-like receptor (TLR) signaling, 45, 191  
topical microbicides, 40, 277  
topoisomerase, 21, 247; 44, 379  
toxicity, mathematical models, 18, 303  
toxicity reversal, 15, 233  
toxicity, structure activity relationships for, 41, 353  
toxicogenomics, 44, 555  
toxicology, comparative, 11, 242; 33, 283  
toxins, bacterial, 12, 211  
transcription factor NF-kB, 29, 235  
transcription, reverse, 8, 251  
transcriptional profiling, 42, 417  
transgenic animals, 24, 207  
transgenic technology, 29, 265  
transient receptor potential modulators, 42, 81  
translational control, 29, 245  
translation initiation inhibition for cancer therapy, 46, 189  
transporters, drug, 39, 219  
traumatic injury, CNS, 25, 31  
triglyceride synthesis pathway, 45, 109  
trophic factors, CNS, 27, 41  
TRPV1 vanilloid receptor, 40, 185  
tumor classification, 37, 225  
tumor necrosis factor, 22, 235  
type 2 diabetes, 35, 211; 40, 167; 47, 159  
tyrosine kinase, 30, 247; 31, 151  
urinary incontinence, 38, 51  
urokinase-type plasminogen activator, 34, 121  
urotensin-II receptor modulators, 38, 99  
vanilloid receptor, 40, 185  
vascular cell adhesion molecule-1, 41, 197  
vascular proliferative diseases, 30, 61  
vasoactive peptides, 25, 89; 26, 83; 27, 79  
vasoconstrictors, 4, 77  
vasodilators, 4, 77; 12, 49  
vasopressin antagonists, 23, 91  
vasopressin receptor ligands, 44, 129  
vasopressin receptor modulators, 36, 159  
veterinary drugs, 16, 161  
virally encoded G protein-coupled receptors, 47, 379

viruses, 14, 238  
vitamin D, 10, 295; 15, 288; 17, 261; 19, 179  
voltage-gated calcium channel antagonists, 45, 5  
waking functions, 10, 21  
water, structures, 5, 256  
Wnt/ $\beta$ -catenin pathway inhibitors, 47, 393  
wound healing, 24, 223  
xenobiotics, cyclic nucleotide metabolism, 15, 182  
xenobiotic metabolism, 23, 315  
X-ray crystallography, 21, 293; 27, 271